Phibro Animal Health Corporation
Nature of Business
Phibro Animal Health Corporation (‘Phibro’) is a global leader in animal health & nutrition and related performance products, with more than 2,500 customers worldwide and a global workforce of around 1,000 employees.
Phibro serves customers globally through manufacturing and distributing more than 550 specialty products. Its combined annual sales are more than $500m. Phibro is headquartered in Teaneck, New Jersey, and has offices across the US and around the world.
3i invested in Phibro in March 2008 to support its international expansion strategy and to allow for a more diverse product portfolio. Since our investment, we have been actively involved in delivering growth in emerging markets, particularly Brazil, Russia, South Africa, India and China. In 2009 we advised on the acquisition of vaccines specialist, ABIC, and nutritionals business, Baltzell.
We have also assisted the company to refinance its existing debt, reviewed a number of international growth opportunities and strengthened the Board with the appointment of Carol Wrenn, the former CEO of Alpharma.
In April 2014 Phibro completed its Initial Public Offering (“IPO”) on NASDAQ offering 14.7 million shares at $15 per share.
Regulatory notice: This asset is managed by 3i Corporation
3i office contact
One Grand Central Place
60 E. 42nd St, Ste 4100
New York, NY 10165
Tel: +1 (212) 848 1400
Fax: +1 (212) 848 1401